Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca - LARVOL DELTA

Longitudinal Proteomic Signatures of Dupilumab and Tralokinumab Treated Atopic Dermatitis Patients. (PubMed, Clin Transl Allergy) - "Dupilumab and tralokinumab effectively target the Th2 axis in AD but their longitudinal systemic immune modulation differs in respect to Th1-Th17 and tissue repair markers."

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immune Modulation • Immunology • Inflammation • IL13 • IL4 • TNFSF11

Comparative disproportionality of adverse events across four type 2 inflammation-targeting biologics for atopic dermatitis: a FAERS analysis of dupilumab, tralokinumab, lebrikizumab, and nemolizumab (EADV 2026) - No abstract available

Adverse events • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation

Comparative Efficacy of Dupilumab, Tralokinumab, and Lebrikizumab on Patient-Reported Outcomes in Moderate-to-Severe Atopic Dermatitis: A Frequentist Network Meta-Analysis (EADV 2026) - No abstract available

Patient reported outcomes • Retrospective data • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Longitudinal laboratory profile of patients with moderate-to-severe atopic dermatitis treated with lebrikizumab or tralokinumab in real-world clinical practice (EADV 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Effectiveness and Safety of Tralokinumab in Korean Patients with Atopic Dermatitis: A Multicenter Retrospective Study (EADV 2026) - No abstract available

Retrospective data • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Multi-Omic Profiling of Skin and Serum Identifies Baseline Predictors of Tralokinumab Response and Resolves Barrier Recovery in Atopic Dermatitis (EADV 2026) - No abstract available

Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Methotrexate enhances the efficacy of tralokinumab in severe atopic dermatitis. (EADV 2026) - No abstract available

Clinical • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Tralokinumab monotherapy rapidly improves sleep, daily functions, and health-related quality of life in patients with atopic dermatitis and moderate-to-severe hand involvement (EADV 2026) - No abstract available

Clinical • HEOR • Monotherapy • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Real-world characterization of early and delayed responses to tralokinumab among patients with atopic dermatitis: Results from the prospective, international, non-interventional 12-month TRACE study (EADV 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Tralokinumab monotherapy improves atopic dermatitis severity in patients with moderate-to-severe atopic hand eczema (EADV 2026) - No abstract available

Clinical • Monotherapy • Contact Dermatitis • Dermatitis • Dermatology • Immunology

Effectiveness of Lebrikizumab as a switch from Tralokinumab in patients with moderate-to-severe atopic dermatitis: a real-world case series (EADV 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Tralokinumab provides early and sustained improvements in head and neck atopic dermatitis among adolescents with moderate-to-severe disease (EADV 2026) - No abstract available

Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Long-term efficacy and safety of tralokinumab in adolescents aged 12–17 years with moderate-to-severe atopic dermatitis (EADV 2026) - No abstract available

Clinical • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Selective modulation of circulating and cutaneous immune responses following tralokinumab treatment in atopic dermatitis (EADV 2026) - No abstract available

Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Real-world use of tralokinumab in patients with atopic dermatitis involving high-burden areas: Effectiveness and impact on quality of life in the prospective, non-interventional 12-month TRACE study (EADV 2026) - No abstract available

Clinical • HEOR • Real-world • Real-world evidence • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Site-Specific Response and Psychosocial Outcomes in Head and Neck Atopic Dermatitis Treated with Tralokinumab: A Prospective Real-World Study. (PubMed, Dermatitis) - "H&N involvement was frequent and may be associated with residual quality-of-life burden despite substantial clinical improvement with tralokinumab."

Journal • Real-world evidence • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Pruritus

Real-World Efficacy and Systemic Immune Modulation Upon Tralokinumab Treatment in Atopic Dermatitis. (PubMed, Clin Transl Allergy) - "In real-world practice, tralokinumab achieves robust clinical benefit and a rebalanced systemic immune pattern. Selective IL-13 blockade reshapes T-cell function, shifting the immune balance from Th2/Th17 dominance toward Th1/regulatory profiles, suggesting immunomodulatory effects consistent with disease modification. Future studies are needed to determine the long-term stability of these immunological changes following treatment prolongation or interruption."

Journal • Real-world evidence • Atopic Dermatitis • Dermatitis • Dermatology • Immune Modulation • Immunology • Pruritus • CD4 • CD8 • IFNG • IL10 • IL13 • IL17A • IL4

Routine blood biomarkers associated with clinical response to tralokinumab in patients with atopic dermatitis: a 48-week real-world study in Japan. (PubMed, Eur J Dermatol) - "The level of TARC may reflect the early therapeutic effects of tralokinumab on both clinical signs and pruritus in patients with AD. IgE may also reflect early treatment response, particularly for clinical signs, whereas LDH may reflect early and mid-term improvement of clinical signs."

Biomarker • Journal • Real-world evidence • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Pruritus

ADUTERCoM: Evaluation by Confocal Reflectance Microscopy of the Skin Structure of Patients With Atopic Dermatitis Treated With Tralokinumab Biotherapy. (clinicaltrials.gov) - P=N/A | N=15 | Active, not recruiting | Sponsor: Hpitaux Drme Nord | Recruiting ➔ Active, not recruiting

Enrollment closed • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Cutaneous lymphomas reported following the use of dupilumab, nemolizumab, tralokinumab, or lebrikizumab: A case investigation based on JADER database and disproportionality analysis. (PubMed, Intractable Rare Dis Res) - "Under these conditions, safety signals based on both the ROR and IC were detected only for dupilumab. The safety signals identified in this study are exploratory in nature and require confirmation in future epidemiological studies."

Journal • Atopic Dermatitis • Cutaneous T-cell Lymphoma • Dermatitis • Dermatology • Hematological Malignancies • Immunology • Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma

Real-World Effectiveness and Safety of 12 Months of Tralokinumab in Patients with Atopic Dermatitis. (PubMed, Dermatol Ther (Heidelb)) - "TRACE is the largest real-world study of tralokinumab to date. Treatment with tralokinumab over 12 months substantially improved signs and symptoms of AD as well as PROs across all outcome measures, providing evidence supporting the rapid and long-term effectiveness of tralokinumab. No new safety signals were identified."

Journal • Real-world evidence • Atopic Dermatitis • Conjunctivitis • Dermatitis • Dermatology • Immunology • Ocular Infections • Ocular Inflammation • Ophthalmology • IL13

Caution in Interpreting Tralokinumab Outcomes in Dupilumab Nonresponders. (PubMed, J Am Acad Dermatol) - No abstract available

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Review on the Application of Biologic Factors in Atopic Dermatitis and Chronic Spontaneous Urticaria. (PubMed, Dermatol Res Pract) - "Dupilumab is ans FDA- and EMA-approved monoclonal antibody, which is effective in 40%-60% of severe AD cases. FDA/EMA-approved are also baricitinib, upadacitinib, and tralokinumab, which could be used as an alternative option...Omalizumab has been used in clinical trials and real-life cases to treat CSU, but a debate on the efficacy of the monoclonal is frequently reported. However, EACCI's current guidelines for the disease include omalizumab as an add-on treatment for recalcitrant cases."

Journal • Review • Atopic Dermatitis • Chronic Spontaneous Urticaria • Dermatitis • Dermatology • Immunology • Urticaria

Pushing the Boundaries of Topical Therapy in Patients with Atopic Dermatitis: A Review of Baseline Disease Severity and Burden in Clinical Trials. (PubMed, Dermatol Ther (Heidelb)) - "Many patients with AD treated in clinical trials of topical therapies report high levels of disease burden, overlapping with some patients eligible for systemic therapies. These results suggest that advanced topical therapies may be effective in patients with more extensive AD."

Clinical • Journal • Review • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Bullous Pemphigoid Disease Area Index Pruritus, Activity, and Damage During Biologic Therapy in Bullous Pemphigoid: An International Dual-Center Study. (PubMed, J Dermatol) - "We conducted a retrospective international dual-center study of 25 patients with bullous pemphigoid treated with dupilumab, omalizumab, or tralokinumab. Although systemic corticosteroids were frequently used at treatment initiation and tapered thereafter, improvement was sustained during corticosteroid weaning. These findings support pruritus as a dynamic and clinically meaningful domain for monitoring treatment response, linked to inflammatory disease activity rather than residual damage."

Journal • Bullous Pemphigoid • Dermatology • Dermatopathology • Immunology • Inflammation • Pruritus